A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma.
combination therapy
hepatocellular carcinoma
immune checkpoint inhibitor
molecular targeted therapy
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
08 09 2022
08 09 2022
Historique:
received:
15
08
2022
revised:
04
09
2022
accepted:
05
09
2022
entrez:
22
9
2022
pubmed:
23
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
Hepatocellular carcinoma remains a leading cause of cancer-related deaths worldwide. Liver disease including cirrhosis and viral hepatitis remains among the leading causes of hepatocellular carcinoma and despite increased screening, many patients are diagnosed in the advanced stages precluding them from locoregional therapy. Therapeutic agents for advanced hepatocellular carcinoma were limited to Sorafenib for several years; however, with the emergence of molecular targeted therapies including tyrosine kinase inhibitors and vascular endothelial growth factor inhibitors, in addition to immunotherapies, the way hepatocellular carcinoma is treated has changed significantly. In this review, we summarize the key clinical trials that lead to the approval of these agents for systemic treatment of hepatocellular carcinoma and discuss the preferred sequence of treatment options as well as prospective studies for management of hepatocellular carcinoma.
Identifiants
pubmed: 36135076
pii: curroncol29090507
doi: 10.3390/curroncol29090507
pmc: PMC9498097
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Vascular Endothelial Growth Factor A
0
Sorafenib
9ZOQ3TZI87
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
6445-6462Références
Lancet Oncol. 2022 Jan;23(1):77-90
pubmed: 34914889
Cancer. 2016 May 1;122(9):1312-37
pubmed: 26959385
Liver Cancer. 2020 Jan;9(1):93-104
pubmed: 32071913
J Hepatocell Carcinoma. 2016 Oct 05;3:41-53
pubmed: 27785449
Eur J Cancer. 2012 Jul;48(10):1452-65
pubmed: 22240282
J Clin Oncol. 2020 Dec 20;38(36):4317-4345
pubmed: 33197225
J Biol Chem. 2001 Dec 28;276(52):49289-98
pubmed: 11682481
Clin Cancer Res. 2020 Sep 15;26(18):4795-4804
pubmed: 32636319
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
J Natl Cancer Inst. 2005 Oct 19;97(20):1532-8
pubmed: 16234567
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Future Oncol. 2020 May;16(15):975-989
pubmed: 32352320
Mol Cancer Ther. 2011 Dec;10(12):2298-308
pubmed: 21926191
Clin Cancer Res. 2009 Feb 1;15(3):971-9
pubmed: 19188168
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Gastroenterology. 2006 Apr;130(4):1117-28
pubmed: 16618406
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
J Hepatol. 2017 Nov;67(5):999-1008
pubmed: 28687477
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Drug Resist Updat. 2020 Jul;51:100702
pubmed: 32371296
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
CA Cancer J Clin. 2017 Jul 8;67(4):273-289
pubmed: 28586094
Mayo Clin Proc Innov Qual Outcomes. 2019 Jul 11;3(3):302-310
pubmed: 31485568
World J Exp Med. 2016 Feb 20;6(1):21-36
pubmed: 26929917
Lancet Oncol. 2020 Jun;21(6):808-820
pubmed: 32502443
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
JAMA Oncol. 2020 Nov 01;6(11):e204564
pubmed: 33001135
Hepatology. 2015 Jan;61(1):184-90
pubmed: 25234419
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Cancer Causes Control. 2018 Sep;29(9):833-844
pubmed: 30030669
Cancer Gene Ther. 2021 Nov;28(10-11):1075-1087
pubmed: 33500535
Cardiovasc Intervent Radiol. 2022 Apr;45(4):405-412
pubmed: 35119481
Int J Clin Pract. 2014 May;68(5):609-17
pubmed: 24283303
Onco Targets Ther. 2021 Dec 29;14:5521-5532
pubmed: 35002257
J Hepatol. 2018 Aug;69(2):353-358
pubmed: 29704513
J Clin Oncol. 2006 Sep 10;24(26):4293-300
pubmed: 16908937
Gastroenterol Hepatol (N Y). 2017 Feb;13(2):122-124
pubmed: 28450818
J Hepatol. 2012 Oct;57(4):821-9
pubmed: 22727733
Future Oncol. 2020 Jul;16(21):1525-1536
pubmed: 32491932
Future Oncol. 2019 Jun;15(16):1811-1822
pubmed: 30969136
J Gastroenterol Hepatol. 2000 Jun;15(6):640-6
pubmed: 10921418
Lancet Oncol. 2015 Jul;16(7):859-70
pubmed: 26095784
Liver Int. 2009 Feb;29(2):284-90
pubmed: 18482274
J Hepatol. 2013 Jul;59(1):81-8
pubmed: 23466307
Cancer Res. 2004 Oct 1;64(19):7099-109
pubmed: 15466206